Tarsus Pharmaceuticals (TARS) Accumulated Expenses (2019 - 2026)

Tarsus Pharmaceuticals' Accumulated Expenses history runs 8 years deep, the most recent figure standing at $8.5 million for Q1 2026.

• In Q1 2026, Accumulated Expenses fell 14.13% year-over-year to $8.5 million; the TTM figure through Mar 2026 stood at $8.5 million (down 14.13% YoY), while the FY2025 annual figure was $17.8 million, up 12.36% from the prior year.
• Accumulated Expenses was $8.5 million for Q1 2026 at Tarsus Pharmaceuticals, down from $17.8 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $17.8 million in Q4 2025 to a low of $1.8 million in Q1 2022.
• Historically, Accumulated Expenses has averaged $8.7 million across 5 years, with a median of $8.0 million in 2024.
• The sharpest annual moves came in 2022 and 2026: Accumulated Expenses surged 163.5% in 2022, then fell 14.13% in 2026.
• A 5-year view of Accumulated Expenses shows it stood at $5.5 million in 2022, then surged by 139.99% to $13.2 million in 2023, then rose by 19.46% to $15.8 million in 2024, then advanced by 12.36% to $17.8 million in 2025, then slumped by 52.03% to $8.5 million in 2026.
• The last three Accumulated Expenses figures came in at $8.5 million (Q1 2026), $17.8 million (Q4 2025), and $13.6 million (Q3 2025), per Business Quant data.